PeptidePlaza
The Free Peptide Reference

Netazepide

From PeptidePlaza, the free peptide reference · Entry #1019 · Metabolic · Sources fetched 2026-09-10 · Editorial standards

Netazepide (also known as Sograzepide, netazepida, netazepidum, Netazepide [INN]) is a metabolic research peptide. Netazepide is a cholecystokinin B receptor antagonist that has been investigated for its potential in treating various gastrointestinal conditions.

Netazepide, also known as Sograzepide, is a cholecystokinin B receptor antagonist. It functions by blocking the activity of the cholecystokinin B receptor. The compound has been studied for its potential applications in conditions such as Barrett Esophagus, Carcinoid Tumor, Zollinger-Ellison Syndrome, Peptic Esophagitis, and Dyspepsia. Its development has reached Phase 2 clinical trials. Research on netazepide includes studies on gastric neuroendocrine tumors and its effects as a gastrin receptor antagonist, with some literature exploring its impact on esomeprazole-induced hypergastrinaemia.

1 Mechanism of action

Cholecystokinin B receptor antagonist (antagonist)

Primary targets: Cholecystokinin B receptor

2 Reported effects

Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.

2.1 Indicated / studied for

  • Barrett Esophagus
  • Carcinoid Tumor
  • Zollinger-Ellison Syndrome
  • Esophagitis, Peptic
  • Dyspepsia

3 Chemical and physical properties

CAS number155488-25-8
Molar mass498.6 g/mol
Purity (typical)Not independently verified
Storage−20 °C, lyophilised powder, desiccated
SolubilitySterile water / bacteriostatic water
Receptors / targetsCholecystokinin B receptor

4 Research studies (8)

  1. Gastric Neuroendocrine Tumors (Carcinoids)
    Current gastroenterology reports (2019) · Review
  2. Gastric neuroendocrine neoplasms: A review
    World journal of clinical cases (2021) · Review
  3. Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice
    The Journal of endocrinology (2016)
  4. Randomised trial of the effect of a gastrin/CCK(2) receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity
    European journal of clinical pharmacology (2017) · RCT
  5. Gastrin: a new branch of the gastropancreatic axis that can explain the effect of sleeve gastrectomy on glucose metabolism
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2024)
  6. CCK(2)R antagonists: from SAR to clinical trials
    Drug discovery today (2020) · Review
  7. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors
    Cellular and molecular gastroenterology and hepatology (2020)
  8. The Autoimmune Gastritis Puzzle: Emerging Cellular Crosstalk and Molecular Pathways Driving Parietal Cell Loss and ECL Cell Hyperplasia
    Cells (2025) · Review

5 Safety and risk profile

5.1 Regulatory status

Netazepide is currently classified as Phase 2 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.

Safety data disclaimer. Safety assessments are based on published literature and are for educational reference only. Clinical evidence varies significantly between peptides. Always consult primary research and current regulatory guidance.

6 Frequently asked questions

What is Netazepide?
Netazepide is a compound classified as a cholecystokinin B receptor antagonist. It is also known by the name Sograzepide and has been the subject of clinical investigations.
How does Netazepide work?
Netazepide functions as an antagonist of the cholecystokinin B receptor. This mechanism involves blocking the activity of this specific receptor, which is relevant in various physiological processes, particularly in the gastrointestinal system.
What is Netazepide used for?
Netazepide has been investigated for several gastrointestinal conditions. These include Barrett Esophagus, Carcinoid Tumor, Zollinger-Ellison Syndrome, Peptic Esophagitis, and Dyspepsia. Its potential therapeutic uses are currently under clinical evaluation.
What is the regulatory status of Netazepide?
Netazepide is currently in Phase 2 clinical trials. This indicates that it is undergoing further evaluation to assess its efficacy and safety for potential medical applications.

7 References

  1. Netazepide — compound summary PubChem. View source
  2. Netazepide — molecule record ChEMBL. View source
  3. Netazepide — published literature (31 records) PubMed. View source

Related compounds

Entries that share a target, a mechanism, or a research area with Netazepide.

Sincalideapproved

Also metabolic

Sincalide, also known as Kinevac, is an FDA-approved cholecystokinin A receptor agonist used in diagnostic imaging and to stimulate pancreatic secretion.

Ceruletide Diethylamineapproved

Also metabolic

Ceruletide Diethylamine is a cholecystokinin A receptor agonist that was FDA approved in 1982.

Gastrinmetabolic

Also metabolic

Gastrin is an endogenous human peptide that stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete digestive enzymes.

Ghrelinmetabolic

Also metabolic

Ghrelin is a peptide hormone that acts as a ligand for the growth hormone secretagogue receptor (GHSR). It is involved in regulating appetite, metabolism, and growth hormone release.

Seractide Acetateapproved

Also metabolic

Seractide Acetate is a synthetic peptide that acts as a melanocortin receptor 2 agonist.

Parathyroid Hormoneapproved

Also metabolic

Parathyroid Hormone is an 84-residue peptide that acts as a parathyroid hormone receptor agonist. It is FDA approved and marketed as Bestmade Natural Products BM67.

8 See also

For research reference only. Not medical advice. Peptides may be regulated or restricted in your jurisdiction. Entry validated by the PeptidePlaza Biomedical Research Desk; see editorial standards.